Risitano, A. M. et al. Complement as a target in COVID-19? Nat. Rev. Immunol. 20, 343–344 (2020).
CAS PubMed Article Google Scholar
Skendros, P. et al. Complement and tissue factor-enriched neutrophil extracellular traps are key drivers in COVID-19 immunothrombosis. J. Clin. Invest. 130, 6151–6157 (2020).
CAS PubMed PubMed Central Article Google Scholar
Afzali, B. et al. The state of complement in COVID-19. Nat. Rev. Immunol. 22, 77–84 (2022).
CAS PubMed Article Google Scholar
Ramlall, V. et al. Immune complement and coagulation dysfunction in adverse outcomes of SARS-CoV-2 infection. Nat. Med. 26, 1609–1615 (2020).
CAS PubMed PubMed Central Article Google Scholar
Wang, E. Y. et al. Diverse functional autoantibodies in patients with COVID-19. Nature 595, 283–288 (2021).
CAS PubMed Article Google Scholar
Lopez, J. et al. Early nasal type I IFN immunity against SARS-CoV-2 is compromised in patients with autoantibodies against type I IFNs. J. Exp. Med. 218, e20211211 (2021).
CAS PubMed PubMed Central Article Google Scholar
Bastard, P. et al. Autoantibodies neutralizing type I IFNs are present in ~4% of uninfected individuals over 70 years old and account for ~20% of COVID-19 deaths. Sci. Immunol. 6, eabl4340 (2021).
PubMed PubMed Central Article Google Scholar
Troya, J. et al. Neutralizing autoantibodies to type I IFNs in >10% of patients with severe COVID-19 pneumonia hospitalized in Madrid, Spain. J. Clin. Immunol. 41, 914–922 (2021).
CAS PubMed PubMed Central Article Google Scholar
Bastard, P. et al. Preexisting autoantibodies to type I IFNs underlie critical COVID-19 pneumonia in patients with APS-1. J. Exp. Med. 218, e20210554 (2021).
CAS PubMed PubMed Central Article Google Scholar
Bastard, P. et al. Autoantibodies against type I IFNs in patients with life-threatening COVID-19. Science 370, eabd4585 (2020).
CAS PubMed PubMed Central Article Google Scholar
Koning, R. et al. Autoantibodies against type I interferons are associated with multi-organ failure in COVID-19 patients. Intensive Care Med. 47, 704–706 (2021).
CAS PubMed PubMed Central Article Google Scholar
de Prost, N. et al. Plasma exchange to rescue patients with autoantibodies against type I interferons and life-threatening COVID-19 pneumonia. J. Clin. Immunol. 41, 536–544 (2021).
PubMed PubMed Central Article CAS Google Scholar
Bastard, P. et al. Interferon-β therapy in a patient with incontinentia pigmenti and autoantibodies against Type I IFNs Infected with SARS-CoV-2. J. Clin. Immunol. 41, 931–933 (2021).
CAS PubMed PubMed Central Article Google Scholar
Pairo-Castineira, E. et al. Genetic mechanisms of critical illness in COVID-19. Nature 591, 92–98 (2021).
PubMed Article CAS Google Scholar
COVID-19 Host Genetics Initiative. Mapping the human genetic architecture of COVID-19. Nature 600, 472–477 (2021).
Kalil, A. C. et al. Efficacy of interferon beta-1a plus remdesivir compared with remdesivir alone in hospitalised adults with COVID-19: a double-bind, randomised, placebo-controlled, phase 3 trial. Lancet Respir. Med. 12, 1365–1376 (2021).
Wilk, J. A. et al. A single-cell atlas of the peripheral immune response in patients with severe COVID-19. Nat. Med. 26, 1070–1076 (2020).
CAS PubMed PubMed Central Article Google Scholar
Wilk, A. J. et al. Multi-omic profiling reveals widespread dysregulation of innate immunity and hematopoiesis in COVID-19. J. Exp. Med. 218, e20210582 (2021).
CAS PubMed PubMed Central Article Google Scholar
Reyes, M. et al. Induction of a regulatory myeloid program in bacterial sepsis and severe COVID-19. Preprint at bioRxiv https://doi.org/10.1101/2020.09.02.280180 (2020).
Article PubMed PubMed Central Google Scholar
Falck-Jones, S. et al. Functional monocytic myeloid-derived suppressor cells increase in blood but not airways and predict COVID-19 severity. J. Clin. Invest. 131, e144734 (2021).
CAS PubMed Central Article Google Scholar
Channappanavar, R. & Perlman, S. Age-related susceptibility to coronavirus infections: role of impaired and dysregulated host immunity. J. Clin. Invest. 130, 6204–6213 (2020).
PubMed PubMed Central Article Google Scholar
Wong, L. R. Eicosanoid signalling blockade protects middle-aged mice from severe COVID-19. Nature 605, 146–151 (2022).
CAS PubMed Article Google Scholar
Gralinski, L. E. et al. Complement activation contributes to severe acute respiratory syndrome coronavirus pathogenesis. mBio 9, e01753-18 (2018).
PubMed PubMed Central Article Google Scholar
Sefik, E. et al. Inflammasome activation in infected macrophages drives COVID-19 pathology. Nature 606, 585–593 (2022).
CAS PubMed Article Google Scholar
Wahl, A. et al. SARS-CoV-2 infection is effectively treated and prevented by EIDD-2801. Nature 591, 451–457 (2021).
CAS PubMed PubMed Central Article Google Scholar
Karki, R. Synergism of TNF-α and IFN-γ triggers inflammatory cell death, tissue damage, and mortality in SARS-CoV-2 infection and cytokine shock syndromes. Cell 184, 149–168 (2021).
CAS PubMed Article Google Scholar
Liu, G. et al. ISG15-dependent activation of the sensor MDA5 is antagonized by the SARS-CoV-2 papain-like protease to evade host innate immunity. Nat. Microbiol. 6, 467–478 (2021).
CAS PubMed PubMed Central Article Google Scholar
Pfaender, S. et al. LY6E impairs coronavirus fusion and confers immune control of viral disease. Nat. Microbiol. 5, 1330–1339 (2020).
CAS PubMed PubMed Central Article Google Scholar
Martin-Sancho, L. et al. Functional landscape of SARS-CoV-2 cellular restriction. Mol. Cell. 81, 2656–2668 (2021).
CAS PubMed PubMed Central Article Google Scholar
Severe Covid-19 GWAS Group. et al. Genomewide association study of severe Covid-19 with respiratory failure. N. Engl. J. Med. 383, 1522–1534 (2020).
Schäfer, A. et al. A multitrait locus regulates sarbecovirus pathogenesis. Preprint at bioRxiv https://doi.org/10.1101/2022.06.01.494461 (2022).
Article PubMed PubMed Central Google Scholar
Krämer, B. et al. Early IFN-α signatures and persistent dysfunction are distinguishing features of NK cells in severe COVID-19. Immunity 54, 2650–2669 (2021).
PubMed PubMed Central Article CAS Google Scholar
Winkler, E. S. SARS-CoV-2 infection of human ACE2-transgenic mice causes severe lung inflammation and impaired function. Nat. Immunol. 21, 1327–1335 (2020).
CAS PubMed PubMed Central Article Google Scholar
Hoagland, D. A. et al. Leveraging the antiviral type I interferon system as a first line of defense against SARS-CoV-2 pathogenicity. Immunity 54, 557–570 (2021).
CAS PubMed PubMed Central Article Google Scholar
Zhang, Q. et al. Inborn errors of type I IFN immunity in patients with life-threatening COVID-19. Science 370, eabd4570 (2020).
CAS PubMed PubMed Central Article Google Scholar
Liu, C. et al. Time-resolved systems immunology reveals a late juncture linked to fatal COVID-19. Cell 184, 1836–1857 (2021).
CAS PubMed PubMed Central Article Google Scholar
Abers, M. S. et al. An immune-based biomarker signature is associated with mortality in COVID-19 patients. JCI Insight 6, e144455 (2021).
PubMed Central Article Google Scholar
Rovina, N. et al. Soluble urokinase plasminogen activator receptor (suPAR) as an early predictor of severe respiratory failure in patients with COVID-19 pneumonia. Crit. Care. 24, 187 (2020).
PubMed PubMed Central Article Google Scholar
Enocsson, H. Soluble urokinase plasminogen activator receptor (suPAR) independently predicts severity and length of hospitalisation in patients with COVID-19. Front. Med. https://doi.org/10.3389/fmed.2021.791716 (2021).
留言 (0)